Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D003328:Coronary Thrombosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D017558:Elective Surgical Procedures; D000077542:Eptifibatide; D006801:Humans; D010455:Peptides / Q000627:therapeutic use*; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D015607:Stents; D013577:Syndrome; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide